Clinical Trial Update: Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib in patients with malignant mesothelioma of the pleura; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Status: COMPLETED